BioSpace News Archive

SQZ Biotechnologies Company today presented preclinical data supporting that tumor infiltrating lymphocytes (TILs) engineered with membrane-bound cytokines IL-2 (mbIL-2) and IL-12 (mbIL-12) may eliminate the need for the high-dose, systemic IL-2 and lymphodepleting preconditioning used with current TIL therapies.

Invitae today announced a collaboration with Simons Searchlight, an international research program with a goal of accelerating research and improving lives for people with rare genetic neurodevelopmental disorders.

Corindus , A Siemens Healthineers Company and a leading developer of precision vascular robotics, announced today it presented the results of a first-of-its-kind study demonstrating the safety and effectiveness of robotic-assisted neurovascular aneurysm embolization using the CorPath GRX Neurovascular System.

Spotlight Therapeutics, Inc. today announced the appointment of Nallakkan Arvindan, Ph.D., MBA as Executive Vice President and Chief Technology Officer.

Science 37 Holdings, Inc. today announced that Michael Shipton has been appointed Chief Commercial Officer to lead business development, strategic solutions, sales operations, and strategic pricing, effective today.

Mersana Therapeutics, Inc. (NASDAQ: MRSN), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer (TNBC).

Crinetics Pharmaceuticals, Inc. announced that on September 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 246,600 shares of its common stock to thirteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced new preclinical data in a murine mesothelioma model showing a substantial and statistically significant survival benefit when Allocetra™ is combined with the chemotherapeutic agent, cisplatin.

Revolo Biotherapeutics (“Revolo” or the “Company”), today announced that it has completed enrollment and has fully randomized all patients in a Phase 2a proof of concept clinical study investigating its immune-resetting molecule, ‘1104, for the treatment of patients with eosinophilic esophagitis (EoE).

AmMax Bio, Inc. announced that Dr. Hans Gelderblom, Professor and Head of Medical Oncology at the Leiden University Medical Centre, will present Phase 2 Pharmacokinetic and Pharmacodynamic Data for the novel local administration of ABM-05X for the treatment of Tenosynovial Giant Cell Tumor on September 12th at the ESMO Congress 2022.